Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin

  1. Robert Raschke, MD, MS;
  2. Jack Hirsh, MD, FCCP; and
  3. James R. Guidry, PharmD
  1. From Good Samaritan Regional Medical Center, Phoenix, Arizona; Henderson Civic Hospital Research Center, Hamilton, Ontario, Canada; and Desert Samaritan Medical Center, Mesa, Arizona.

    Abstract

    Background: Site-specific validation of the activated partial thromboplastin time (aPTT) therapeutic range is required to ensure administration of the optimal dose of unfractionated heparin. Therapeutic ranges of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents.

    Purpose: To audit the appropriateness of aPTT monitoring in clinical trials comparing unfractionated heparin and low-molecular-weight heparin in patients with venous thromboembolism.

    Data Sources: Search of PubMed database from 1984 to 2001.

    Study Selection: Randomized, controlled trials that compared unfractionated and low-molecular-weight heparin for the treatment of venous thromboembolism.

    Data Extraction: Use of unvalidated and potentially suboptimal therapeutic ranges for aPTT in patients assigned to receive unfractionated heparin.

    Data Synthesis: Fifteen studies met inclusion criteria. Only 3 studies used a validated aPTT therapeutic range, and 11 studies used a range that included aPTT values 1.5 times the control value. Ten studies reported unfractionated heparin doses, and 7 of these documented a reduction to less than 30 000 U/d in response to aPTT results.

    Conclusions: Most studies monitored unfractionated heparin inappropriately. This shortcoming could be responsible for the reduced efficacy of unfractionated heparin in clinical trials.

    Article and Author Information

    • Potential Financial Conflicts of Interest:Honoraria: R. Raschke (Aventis).

    • Requests for Single Reprints: Robert Raschke, MD, MS, Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, AZ 85006; e-mail, robertraschke{at}bannerhealth.com.

    • Current Author Addresses: Dr. Raschke: Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, AZ 85006.

    • Dr. Hirsh: Henderson Civic Hospital Research Center, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada.

    • Mr. Guidry: Clinical Pharmacy, Desert Samaritan Medical Center, 1400 South Dobson Road, Mesa, AZ 85202.

    • Author Contributions: Conception and design: R. Raschke, J. Hirsh, J.R. Guidry.

    • Analysis and interpretation of the data: R. Raschke, J. Hirsh, J.R. Guidry.

    • Drafting of the article: R. Raschke, J.R. Guidry.

    • Critical revision of the article for important intellectual content: R. Raschke, J. Hirsh, J.R. Guidry.

    • Final approval of the article: R. Raschke, J. Hirsh, J.R. Guidry.

    • Provision of study materials or patients: R. Raschke, J.R. Guidry.

    • Statistical expertise: R. Raschke.

    • Administrative, technical, or logistic support: R. Raschke, J.R. Guidry.

    • Collection and assembly of data: R. Raschke, J.R. Guidry.

    Summary for Patients

    • Summaries for Patients:What Is the Most Effective Blood Thinner for Treating Patients with Blood Clots in the Veins? Ann Intern Med May 6, 2003 138:I-63
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med May 6, 2003 vol. 138 no. 9 720-723
    1. » Abstract
    2. Full Text
    3. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues